Clinical trials: LSD
LSD
Drug Effects on Mood and Behavior - Expectancy
This study will examine the effects of a single low dose of the 5HT2A agonist LSD (Lysergic Acid Diethylamide) (13 µg) or placebo in individuals who are or are not explicitly told what drug they will receive.
- Trial name
- MESA-X (NCT07061886)
- Testing
- LSD
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Healthy
Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study
The purpose of this study is to characterize the acute psychological, physiological, endocrine, and pharmacokinetic, as well as long-term psychological effects of LSD in humans.
- Trial name
- NCT01878942
- Testing
- LSD
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
PMS, PMDD
Microdosing LSD in Women With Premenstrual Disorders
The investigators aim to investigate the role of the serotonin 2A receptor in women with premenstrual disorders. This study uses a double-blind, randomized, controlled design with 3 arms: Intervention 1: 10 micg LSD for ~10 days…
- Trial name
- L4Her (NCT07189299)
- Testing
- LSD 10 μg every Day, LSD 10 μg every other day
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- Friederike Holze
Anxiety Generalized
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects…
- Trial name
- NCT05407064
- Testing
- MM120
- Where
- 22 sites in United States
- Volunteers
- 198 people
- Sponsor
- Definium Therapeutics US, Inc.
Lysosomal Storage Diseases, Cystinosis
Stem Cell Gene Therapy for Cystinosis
This study is a Phase 1/2 clinical trial that will assess the safety and efficacy of enriched gene-corrected hematopoietic stem cells isolated from patients affected with cystinosis.
- Trial name
- NCT03897361
- Testing
- CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Diego
Healthy
Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects
The acute subjective effects of serotonin (5-HT)2A receptor stimulation with lysergic acid diethylamide (LSD) in humans are mostly positive.
- Trial name
- LSD-MDMA (NCT04516902)
- Testing
- Lysergic Acid Diethylamide, 3,4-methylenedioxymethamphetamine
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
LSD, Major Depressive Disorder
Mood Effects of Serotonin Agonists: Depression
This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression.
- Conditions
- LSD, Major Depressive Disorder, Depression
- Trial name
- MESA-D (NCT07017478)
- Testing
- LSD
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Cirrhosis, Liver, Splenectomy; Status
Effect of LSD on Lipid Profiles in Cirrhosis Patients With Portal Hypertension Bleeding (2-Year Follow-Up)
Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension.
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Portal Hypertension, Lipid Profiles
- Trial name
- LSD-LPPH (NCT07588334)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Healthy
Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin
LSD (lysergic acid diethylamide) and psilocybin (the active substance in "magic mushrooms") are widely used for recreational purposes.
- Trial name
- LSD-psilo (NCT03604744)
- Testing
- LSD, Psilocybin
- Where
- Switzerland
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Healthy
Effects of LSD on Neuroplasticity in Healthy Subjects
Neuroplasticity is the brain's ability to reorganize itself and adapt in response to changing environmental conditions or pathological stimuli.
- Trial name
- NCT05177419
- Testing
- Lysergic Acid Diethylamide
- Where
- Switzerland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Fribourg
Anxiety
Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety
This study will find out whether psychotherapy combined with lysergic acid diethylamide (LSD) is safe and is helpful in people who are anxious because they have a potentially fatal disease.
- Trial name
- NCT00920387
- Testing
- 200 mcg LSD, 20 mcg LSD, Therapy
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Multidisciplinary Association for Psychedelic Studies
Major Depressive Disorder (MDD), Anxiety Disorders
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
This retrospective observational study examines the effects of psychedelic-assisted psychotherapy (PAP) with lysergic acid diethylamide (LSD) or psilocybin in patients with treatment-resistant depressive, anxiety, or addictive…
- Conditions
- Major Depressive Disorder (MDD), Anxiety Disorders, Substance Use Disorder (SUD), PTSD - Post Traumatic Stress Disorder
- Trial name
- NCT07164287
- Testing
- Lysergic Acid Diethylamide (LSD) or psilocybin
- Where
- Switzerland
- Volunteers
- 376 people
- Sponsor
- University Hospital, Geneva
Mucopolysaccharidosis IVA, Morquio A Syndrome
BMN 110 US Expanded Access Program
The Expanded Access Program (EAP) is an open-label, multicenter program to: 1. Provide patients who have been diagnosed with Mucopolysaccharidosis IVA (MPS IVA) access to BMN 110 until commercial product is available 2.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01858103
- Testing
- BMN 110
- Where
- 25 sites in United States, Puerto Rico
- Sponsor
- BioMarin Pharmaceutical
Mucopolysaccharidosis IVA, Morquio A Syndrome
Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)
This open-label Phase 2 study will evaluate the safety and efficacy of weekly 2.0 mg/kg/wk infusions of BMN 110 in pediatric patients, less than 5 years of age at the time of administration of the first dose of study drug…
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01515956
- Testing
- BMN 110
- Where
- 5 sites in United States, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- BioMarin Pharmaceutical
Healthy
Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects
Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic acting on the serotonin 5-HT2A receptor. LSD is used recreationally and in psychiatric research.
- Trial name
- SERT-LSD (NCT05175430)
- Testing
- Paroxetine, Lysergic Acid Diethylamide
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Prosocial Behavior
The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality
The goal of this study is to assess the effects of LSD on neural synchrony, prosocial behavior, and relationship quality in healthy romantic couples.
- Trial name
- NCT05670184
- Testing
- LSD, Ethanol
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Maastricht University
Chronic Cluster Headache
LSD to Improve Cluster Headache Impact Trial
This study aims to investigate the efficacy and safety of LSD 25μg every 3 days for 3 weeks versus placebo in the treatment of chronic cluster headache (cCH).
- Trial name
- LICIT (NCT05477459)
- Testing
- LSD tartrate
- Where
- 2 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- Radboud University Medical Center
Cirrhosis, Liver, Splenectomy; Status
Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension
Patients with liver cirrhosis and portal hypertension often have impaired kidney function due to reduced blood flow to the kidneys and fluid buildup in the abdomen (ascites).
- Conditions
- Cirrhosis, Liver, Splenectomy; Status, Renal Function Abnormal, Portal Hypertension
- Trial name
- NCT07811713
- Testing
- Laparoscopic splenectomy and azygoportal disconnection
- Volunteers
- 496 people
- Sponsor
- Northern Jiangsu People's Hospital
Mucopolysaccharidosis IVA, Morquio A Syndrome
Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation
The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01697319
- Testing
- BMN 110
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 16 people
- Sponsor
- BioMarin Pharmaceutical
MPS IV A, Mucopolysaccharidosis IVA
A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
This multicenter, multinational, longitudinal study will quantify endurance and respiratory function in subjects diagnosed with MPS IVA and will better characterize the spectrum of symptoms and biochemical abnormalities in MPS…
- Conditions
- MPS IV A, Mucopolysaccharidosis IVA, Morquio A Syndrome
- Trial name
- NCT00787995
- Where
- 15 sites in United States, Argentina and 8 more
- Volunteers
- 353 people
- Sponsor
- BioMarin Pharmaceutical